Company Overview
About Exin Therapeutics
Exin Therapeutics is a San Francisco-based AI-powered neurotherapeutics drug discovery company — pioneering genetic therapies that target neural activity to treat epilepsy, autism spectrum disorder symptoms, Parkinson's disease, and other neurological conditions using a multimodal AI platform that predicts therapeutic candidate potential across multiple neural disorders simultaneously. Using neural activity recordings, behavioral assays, and transcriptomics data as inputs, Exin's AI models identify genetic intervention targets and predict therapeutic outcomes before entering animal studies — compressing the target identification timeline that traditional neuroscience drug discovery requires. The company established an animal research facility, obtained proof-of-concept results in mice, and filed two provisional patents within 1.5 months of San Francisco operations, and is investing approximately $25 million to build the Philippines' first neurotherapeutics laboratory.
Business Model & Competitive Advantage
Exin's AI neurotherapeutics platform addresses the target identification challenge that makes central nervous system drug development the most difficult therapeutic area: the brain's complexity (100 billion neurons with 100 trillion synaptic connections expressing 30,000+ genes) means that identifying which genes, circuits, or signaling pathways to target for a given neurological condition requires integrating multi-modal data types that traditional bioinformatics pipelines analyze separately. Exin's multimodal AI (simultaneously training on electrophysiology (neural firing patterns), behavioral data (movement, seizure frequency, social behavior), and transcriptomics (gene expression profiles)) learns the relationships between molecular interventions and functional neural outcomes — enabling the company to predict which genetic therapy strategies will modulate neural activity in therapeutically beneficial directions before expensive and time-consuming in vivo studies.
Competitive Landscape 2025–2026
In 2025, Exin Therapeutics competes in the AI drug discovery, gene therapy, and CNS therapeutics market with Recursion Pharmaceuticals (NASDAQ: RXRX, AI drug discovery, $400M+ raised), Invaio Sciences (agricultural neuroscience, different sector), and Prevail Therapeutics (NASDAQ: PRVL, AAV gene therapy, acquired by Eli Lilly for $1.04B) for AI-powered neurological disease genetic therapy discovery and development adoption. The Philippines laboratory investment ($25M commitment) represents a significant geographic and infrastructure bet on building neurotherapeutics research capacity in Southeast Asia. The provisional patent filings validate novel intellectual property in the AI-neural target identification space. The 2025 strategy focuses on advancing the epilepsy genetic therapy lead program toward formal IND filing, building the human neural organoid validation system for translational prediction accuracy, and developing the Parkinson's disease gene therapy pipeline leveraging the multimodal AI platform's dopaminergic circuit modeling.
Recent Activity
View all →Company Timeline
Major milestones in Exin Therapeutics's journey
Leadership Team
Meet the leaders behind Exin Therapeutics
Dr. Gabriel Ocana Santero
Dr. Ivan Lazarte
Marko Tvrdic
Key Differentiators
Emerging Innovator
Exin Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Novatr
Novatr is a Gurugram-based edtech company providing professional upskilling courses for architects, engineers, and designers in Building Information Modeling (BIM), computational design, and Revit — t
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Compare Exin Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Exin Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Exin Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Exin Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →